目前的药理选择和治疗治疗治疗性结肠炎的新兴治疗方法:叙述性审查
Sneha Annie Sebastian1, Oroshay Kaiwan2, Edzel L Co3
1Department of Internal Medicine Edgemont Medical Centre, Calgary, Canada.
Spartan medical research journal
|September 16, 2024
概括
性结肠炎 (UC) 管理正在随着针对炎症的新疗法而发展. 本综述涵盖了UC的标准治疗方法和新兴选择,包括新型配方和生物制剂.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠道疾病 (IBD),其特征是复发和缓解的时期.
- 传统疗法,如5-aminosalicylates (5-ASAs),硫素 (SASP),皮质类固醇和免疫调节剂一直是UC治疗的主要支柱.
- 临床研究的进步为UC管理引入了新的配方和新的治疗目标.
研究的目的:
- 提供当前和新兴治疗性结肠炎的全面概述.
- 讨论标准治疗方法和新型治疗方法的潜在好处.
- 在UC管理中突出新化学实体和配方.
主要方法:
- 这项研究是对性结肠炎疗法现有文献的叙事性综述.
- 它综合了关于标准治疗和新型治疗策略的信息.
- 该审查侧重于配方,化学实体和治疗方法的进展.
主要成果:
- 传统药物如5-ASAs,SASP,皮质类固醇和免疫调节剂仍然很重要.
- 新的配方和剂量方案正在改变治疗序列.
- 针对特定炎症机制的几种新药正在开发的后期阶段或最近获得批准.
结论:
- 标准疗法随着新配方和治疗方案的不断发展而不断发展.
- 新兴疗法,包括生物药物和新的化学实体,为UC提供了有针对性的方法.
- 本综述提供了关于UC管理不断变化的情景的见解,强调了新的治疗策略.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Peptic Ulcer Disease IV: Management
75
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
75
Inflammatory Bowel Disease V: Surgical Management
128
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
128
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98


